Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Medical News & Perspectives article entitled "FDA Weighs
Communicating Drug-Related Risk to Patients" published in the August 11, 1999,
issue of THE JOURNAL (1999;282:515), the words "troglitazone (Rezulin, used
for type 2 diabetes)" should be deleted. No written informed consent has been
recommended or advised in connection with the prescription of this drug.
Incorrect Information. JAMA. 1999;282(15):1425. doi:10.1001/jama.282.15.1425
Create a personal account or sign in to: